Sarah Glewis is a Senior Clinical Pharmacogenomics Pharmacist at Peter MacCallum Cancer Centre and a PhD Candidate at the University of Melbourne, Australia. Her current research efforts focus on clinical Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) for the treatment and supportive care of cancer. She is the principal investigator for the first PGx multisite clinical trial in Australia (PACIFIC-PGx) and program manager for the follow-on trial with expanded PGx testing and TDM (PRECISION). She was awarded a research grant from ISOPP to support her PGx research work extending to regional areas in Australia and her work in PGx has been recognized in the Victorian HealthCare Award in Australia.

Claire is a pharmacist-scientist who has recently completed her PhD in the implementation of pharmacogenomics in paediatric oncology. She works in the Children's Cancer Centre, The Royal Children's Hospital, Melbourne as a pharmacogenomics pharmacist and is a Research Fellow at the Murdoch Children's Research Institute.

Dr Stefanie Lip is a Clinical Senior Lecturer in Pharmacogenomics at the University of Glasgow and an Honorary Consultant at the Queen Elizabeth University Hospital (NHS Greater Glasgow & Clyde). Her research focuses on pharmacogenomics and hypertension.

Yining Luo is a PhD candidate at the Sydney Pharmacy School, the University of Sydney. Her research focuses on transporter-guided drug design, with an emphasis on understanding how human solute carrier transporters influence drug disposition and toxicity. Her current research investigates interactions between polymyxin antibiotics and human oligopeptide transporter 2 (hPepT2), a key mechanism underlying polymyxin-induced nephrotoxicity. Her interests include drug discovery and the development of safer antibiotics.

Siobhonne Breen is a PhD candidate at the Monash Faculty of Pharmacy and Pharmaceutical Science, rationally optimising antibiotic combinations against resistant bacterial 'superbugs'. Siobhonne's project encompasses a range of laboratory work as well as mechanism-based mathematical modelling, both of which she has a strong interest in. Siobhonne has a passion for improving patient outcomes through drug research and development. Siobhonne has won multiple poster presentation awards and received oral presentations at international and national conferences.

Getnet Assefa holds a BSc in Pharmacy and an MSc in Pharmacology. He is a PhD candidate in the Antimicrobial Optimization Group at the University of Queensland Centre for Clinical Research (UQCCR). His research focuses on pharmacokinetic/pharmacodynamic (PK/PD) optimization of antimicrobial agents, particularly β-lactamase inhibitors in combination with β-lactam antibiotics, in critically ill patients. He specializes in dose optimization using dynamic hollow-fiber infection models (HFIM), with findings translated into clinical practice under the supervision of Dr. Fekade Sime. He also contributes to population pharmacokinetic studies of antimicrobials in collaboration with experts at UQCCR, led by Professor Jason Roberts. His technical expertise includes systematic review and meta-analysis; in vitro infection models (MIC testing, time-kill experiments, HFIM, DNA extraction, and quantification); popPK modeling; probability of target attainment analysis using Monolix and Simulx; and strong communication and scientific writing skills. He has published more than 25 peer-reviewed articles in reputable journals.